Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia
Introduction: Ramucirumab (Ram), a human IgG 1 antibody against vascular endothelial growth factor receptor 2. This multicenter retrospective study aims to reviewed the results of Ram-based therapy as second-line treatment in patients with advanced gastric cancer in a real-life setting.Methods: it w...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2019-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/5238 |
| _version_ | 1827961622246719488 |
|---|---|
| author | N. S. Besova T. A. Titova E. V. Artamonova D. L. Stroyakovskiy E. V. Perminova D. Yu. Yukal’chuk D. M. Ponomarenko N. P. Belyak R. V. Orlova G. M. Teletaeva E. Yu. Ratner A. S. Mochalova O. O. Gordeeva A. S. Zhabina S. V. Gamayunov A. V. Smolin A. Yu. Povyshev M. I. Andrievskikh A. A. Tryakin I. S. Stilidi |
| author_facet | N. S. Besova T. A. Titova E. V. Artamonova D. L. Stroyakovskiy E. V. Perminova D. Yu. Yukal’chuk D. M. Ponomarenko N. P. Belyak R. V. Orlova G. M. Teletaeva E. Yu. Ratner A. S. Mochalova O. O. Gordeeva A. S. Zhabina S. V. Gamayunov A. V. Smolin A. Yu. Povyshev M. I. Andrievskikh A. A. Tryakin I. S. Stilidi |
| author_sort | N. S. Besova |
| collection | DOAJ |
| description | Introduction: Ramucirumab (Ram), a human IgG 1 antibody against vascular endothelial growth factor receptor 2. This multicenter retrospective study aims to reviewed the results of Ram-based therapy as second-line treatment in patients with advanced gastric cancer in a real-life setting.Methods: it was an observational, retrospective study carried out in 11 Russian hospitals. Endpoints included safety, overall survival (OS), progression-free survival (PFS), objective response rate (ORR).Results: 163 patients were included. Ram was used as the second- line in 166 combined with weekly paclitaxel (PTX) in 104 patients or irinotecan-based chemotherapy (mostly FOLFIRI) in 42 patients and as monotherapy in 17 patient. In second line VEGF-related toxicity (all grades) included epistaxis (39,2%), proteinuria >1g/day (4.9%), and arterial hypertension (68%); grade 3-4 toxicity was bleeding (4.3%), perforation (2,4%), venous thrombosis (6,13%) and brain ischemia (0.6%, grade 5). 15 patients (9,2%) discontinued therapy due to toxicity.Conclusion: These real-life efficacy data of ramucirumab are in line with previous randomized trials. Ramucirumab is well tolerated in daily clinical practice. |
| first_indexed | 2024-04-09T16:29:35Z |
| format | Article |
| id | doaj.art-585c4f001e1d4aa6b26c7d34d605422b |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:29:35Z |
| publishDate | 2019-12-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-585c4f001e1d4aa6b26c7d34d605422b2023-04-23T06:57:10ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902019-12-0101910411310.21518/2079-701X-2019-19-104-1134758Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of RussiaN. S. Besova0T. A. Titova1E. V. Artamonova2D. L. Stroyakovskiy3E. V. Perminova4D. Yu. Yukal’chuk5D. M. Ponomarenko6N. P. Belyak7R. V. Orlova8G. M. Teletaeva9E. Yu. Ratner10A. S. Mochalova11O. O. Gordeeva12A. S. Zhabina13S. V. Gamayunov14A. V. Smolin15A. Yu. Povyshev16M. I. Andrievskikh17A. A. Tryakin18I. S. Stilidi19Federal State Budgetary Institution «N.N. Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian FederationFederal State Budgetary Institution «N.N. Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian FederationFederal State Budgetary Institution «N.N. Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian FederationMoscow State Budgetary Healthcare Institution «Moscow City Oncology Hospital No. 62 of the Moscow City Health Department»Moscow State Budgetary Healthcare Institution «Moscow City Oncology Hospital No. 62 of the Moscow City Health Department»State Budget Healthcare Institution «Regional Cancer Center»State Budget Healthcare Institution «Regional Cancer Center»Saint Petersburg State Healthcare Institution «City Clinical Oncology Center»Federal State Budgetary Educational Institution of Higher Education «Saint Petersburg State University», Saint Petersburg State Healthcare Institution «City Clinical Oncology Center»Federal State Budgetary Institution «Petrov National Medical Cancer Research Centre» of the Ministry of Health of the Russian FederationState Autonomous Healthcare Institution «Tatarstan Regional Clinical Cancer Center» of the Ministry of Health of the Russian FederationMedsi Group JSCFederal State Budgetary Institution «N.N. Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian FederationPetrov National Medical Cancer Research Centre of the Ministry of Health of the Russian FederationA.F. Tsyb Medical Radiological Research Centre – Branch of Federal State Budgetary Institution «National Medical Research Radiological Center» of the Ministry of Health of the Russian FederationFederal State Budget Institution «Main Military Clinical Hospital named after N.N. Burdenko»Budgetary Institution of Higher Education of the KhantyMansi Autonomous District - Yugra «Khanty-Mansiysk State Medical Academy»State Budgetary Healthcare Institution «Chelyabinsk Regional Clinical Center for Oncology and Nuclear Medicine»Federal State Budgetary Institution «N.N. Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian FederationFederal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation, Federal State Budgetary Educational Institution of Higher Education «Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian FederationIntroduction: Ramucirumab (Ram), a human IgG 1 antibody against vascular endothelial growth factor receptor 2. This multicenter retrospective study aims to reviewed the results of Ram-based therapy as second-line treatment in patients with advanced gastric cancer in a real-life setting.Methods: it was an observational, retrospective study carried out in 11 Russian hospitals. Endpoints included safety, overall survival (OS), progression-free survival (PFS), objective response rate (ORR).Results: 163 patients were included. Ram was used as the second- line in 166 combined with weekly paclitaxel (PTX) in 104 patients or irinotecan-based chemotherapy (mostly FOLFIRI) in 42 patients and as monotherapy in 17 patient. In second line VEGF-related toxicity (all grades) included epistaxis (39,2%), proteinuria >1g/day (4.9%), and arterial hypertension (68%); grade 3-4 toxicity was bleeding (4.3%), perforation (2,4%), venous thrombosis (6,13%) and brain ischemia (0.6%, grade 5). 15 patients (9,2%) discontinued therapy due to toxicity.Conclusion: These real-life efficacy data of ramucirumab are in line with previous randomized trials. Ramucirumab is well tolerated in daily clinical practice.https://www.med-sovet.pro/jour/article/view/5238ramucirumabgastric canceririnotecanfluoropyrimidine adenocarcinomasecond line treatment |
| spellingShingle | N. S. Besova T. A. Titova E. V. Artamonova D. L. Stroyakovskiy E. V. Perminova D. Yu. Yukal’chuk D. M. Ponomarenko N. P. Belyak R. V. Orlova G. M. Teletaeva E. Yu. Ratner A. S. Mochalova O. O. Gordeeva A. S. Zhabina S. V. Gamayunov A. V. Smolin A. Yu. Povyshev M. I. Andrievskikh A. A. Tryakin I. S. Stilidi Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia Медицинский совет ramucirumab gastric cancer irinotecan fluoropyrimidine adenocarcinoma second line treatment |
| title | Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia |
| title_full | Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia |
| title_fullStr | Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia |
| title_full_unstemmed | Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia |
| title_short | Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia |
| title_sort | tolerance of ramucirumab in the second line therapy of patients with disseminated gastric cancer in the routine clinical practice of russia |
| topic | ramucirumab gastric cancer irinotecan fluoropyrimidine adenocarcinoma second line treatment |
| url | https://www.med-sovet.pro/jour/article/view/5238 |
| work_keys_str_mv | AT nsbesova toleranceoframucirumabinthesecondlinetherapyofpatientswithdisseminatedgastriccancerintheroutineclinicalpracticeofrussia AT tatitova toleranceoframucirumabinthesecondlinetherapyofpatientswithdisseminatedgastriccancerintheroutineclinicalpracticeofrussia AT evartamonova toleranceoframucirumabinthesecondlinetherapyofpatientswithdisseminatedgastriccancerintheroutineclinicalpracticeofrussia AT dlstroyakovskiy toleranceoframucirumabinthesecondlinetherapyofpatientswithdisseminatedgastriccancerintheroutineclinicalpracticeofrussia AT evperminova toleranceoframucirumabinthesecondlinetherapyofpatientswithdisseminatedgastriccancerintheroutineclinicalpracticeofrussia AT dyuyukalchuk toleranceoframucirumabinthesecondlinetherapyofpatientswithdisseminatedgastriccancerintheroutineclinicalpracticeofrussia AT dmponomarenko toleranceoframucirumabinthesecondlinetherapyofpatientswithdisseminatedgastriccancerintheroutineclinicalpracticeofrussia AT npbelyak toleranceoframucirumabinthesecondlinetherapyofpatientswithdisseminatedgastriccancerintheroutineclinicalpracticeofrussia AT rvorlova toleranceoframucirumabinthesecondlinetherapyofpatientswithdisseminatedgastriccancerintheroutineclinicalpracticeofrussia AT gmteletaeva toleranceoframucirumabinthesecondlinetherapyofpatientswithdisseminatedgastriccancerintheroutineclinicalpracticeofrussia AT eyuratner toleranceoframucirumabinthesecondlinetherapyofpatientswithdisseminatedgastriccancerintheroutineclinicalpracticeofrussia AT asmochalova toleranceoframucirumabinthesecondlinetherapyofpatientswithdisseminatedgastriccancerintheroutineclinicalpracticeofrussia AT oogordeeva toleranceoframucirumabinthesecondlinetherapyofpatientswithdisseminatedgastriccancerintheroutineclinicalpracticeofrussia AT aszhabina toleranceoframucirumabinthesecondlinetherapyofpatientswithdisseminatedgastriccancerintheroutineclinicalpracticeofrussia AT svgamayunov toleranceoframucirumabinthesecondlinetherapyofpatientswithdisseminatedgastriccancerintheroutineclinicalpracticeofrussia AT avsmolin toleranceoframucirumabinthesecondlinetherapyofpatientswithdisseminatedgastriccancerintheroutineclinicalpracticeofrussia AT ayupovyshev toleranceoframucirumabinthesecondlinetherapyofpatientswithdisseminatedgastriccancerintheroutineclinicalpracticeofrussia AT miandrievskikh toleranceoframucirumabinthesecondlinetherapyofpatientswithdisseminatedgastriccancerintheroutineclinicalpracticeofrussia AT aatryakin toleranceoframucirumabinthesecondlinetherapyofpatientswithdisseminatedgastriccancerintheroutineclinicalpracticeofrussia AT isstilidi toleranceoframucirumabinthesecondlinetherapyofpatientswithdisseminatedgastriccancerintheroutineclinicalpracticeofrussia |